Accord Healthcare launch biosimilar filgrastim in Europe

January 27, 2015 2:30 PM


Following the CHMP approval in July last year, Accord Healthcare has announced the launch of their first European approved biopharmaceutical product Accofil®, indicated for the treatment of chemotherapy induced neutropenia.

Accofil is a biopharmaceutical product with the same range of indications as Neupogen (filgrastim) and will offer patients comparable quality, safety and efficacy combined with cost-effectiveness.

Accofil has incorporated additional features for improved patient safety and better product handling.

  • Class-leading stability data* – 15 days physico-chemical stability at room temperature
  • Clear graduation on syringe to aid accurate dosing and minimise the risk of errors in administration
  • Passive needle guard protection device to reduce needle stick injuries, minimising the risk of blood borne infections
  • Strength colour differentiation to improve identification
  • Individual blister packaging to preserve product integrity and allow storage optimisation
  • Packaging design with safety features that may improve handling

Mr Binish Chudgar, Vice- Chairman and Managing Director commented “The launch of Accofil demonstrates Accord Healthcare’s commitment to bringing high quality and affordable biopharmaceutical products to the European market. We are proud that Accofil, which was developed by our own research scientists, manufactured at our GMP approved biopharmaceutical site, and has been available for 10 years in other countries, showcases our expertise in biopharmaceutical development and manufacture. This is the first of many biological products we are in the process of bringing to the EU market over the coming years”.


Source: Accord Healthcare

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!